Diabetic Neuropathy Clinical Trial
Official title:
The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy
Verified date | May 2021 |
Source | Loma Linda University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this graduate student research study is to explore the effects of a new treatment known as Intraneural facilitation (INF) on Diabetes Mellitus Type 2 (DMT2) subjects who have moderate - severe below ankle neuropathy symptoms. Since INF has shown success in the clinic and significant improvements have been found in a recent pilot study, this study aims to further explore these effects on DMT2 subjects suffering from DPN. The investigators would like to investigate if INF improves blood flow in the foot, if it decreases the pain and improves the sensation, and if it improves the overall quality of life.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 10, 2020 |
Est. primary completion date | December 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients with Diabetes Type 2 and Diabetic Peripheral Neuropathy with no other known underlying disease - Below ankle Diabetic Peripheral Neuropathy symptoms (numbness, tingling, burning, sharp pain, increased sensitivity, etc.) - =10 on Quality of Life- Diabetic Neuropathy Scale (QOL- DN) - Between age 50-75 years Exclusion Criteria: - Patients with a medical condition that suggested possible decline in function over the next 6 months such as; a current regimen of chemotherapy, radiation therapy, or dialysis - Any lower extremity amputations or wounds - Documented active alcohol and/or drug misuse - Known health conditions: end stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease and active inflammations - DM patients with inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy (CIDP), proximal diabetes neuropathy, and autonomic neuropathies - Patients with other types of neuropathies not associated with Diabetes Mellitus such as B12 deficiency, hypothyroidism, and uremia - Other severe chronic medical condition requiring active treatment - Morbidly Obese patients - Pregnancy (self reported) |
Country | Name | City | State |
---|---|---|---|
United States | Loma Linda University | Loma Linda | California |
Lead Sponsor | Collaborator |
---|---|
Loma Linda University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain Quality Assessment Scale | It is a self-report tool derived from Neuropathic Pain Scale to evaluate the quality of neuropathic pain. After reading the introduction of the questionnaire, subjects will then measure their pain on a numeric scale 0= "no pain" or "no painful sensation" to 10 = "worst imaginable pain sensation" . A zero score represents the best outcome and a 10 is the worst outcome. This questionnaire takes approximately 10 minutes. | change between baseline and 5 weeks | |
Secondary | Limits of Stability | The LOS test will assess the subjects weight-shifting ability and voluntary limits of stability to eight directional targets set at 100% of theoretical limits of stability for an eight second hold. The LOS test measures five parameters: reaction time, movement velocity, end point excursion, maximum excursion, and directional control. We will take the composite scores of reaction time, movement velocity, end point excursion, maximum excursion, and directional control from the 8 directions. This test should take 10 minutes. | change between baseline and 5 weeks | |
Secondary | Zeno Walkway | The Zeno Walkway is used to observe the spatiotemporal characteristics of gait in the subjects: velocity and stride length. Participants will be wearing their own shoes and will be instructed prior to arrival to wear comfortable shoes without heels. The subjects will be asked to walk back and forth the walkway 4 times. This test will take 5 minutes. | change between baseline and 5 weeks | |
Secondary | Sensory organization test (SOT) | The SOT will assess the subject's use of visual, somatosensory, and vestibular systems for maintaining upright posture. The standardized test instructions, per NeuroCom protocol, were either "stand quietly with your eyes open" or "stand quietly with your eyes closed" depending on the condition being tested. This test is completed under six different sensory conditions lasting 20 seconds each.
Step 1 the patient is required to stand still with eyes open (all sensory information available) Step 2 the patient is required to stand still with their eyes closed Step 3 the surrounding moves as the patient moves Step 4 the force plate moves as the patient moves Step 5 the patient closes their eyes and the force plate moves as the patient moves Step 6 the surrounding and force plate move as the patient moves This test should take 10 minutes. |
change between baseline and 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02659007 -
Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga
|
Phase 1 | |
Completed |
NCT01953757 -
A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)
|
N/A | |
Completed |
NCT01707979 -
NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes
|
N/A | |
Completed |
NCT00608439 -
Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00576277 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT00830011 -
Cognitive Behavioral Therapy for Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT00235443 -
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00931879 -
Lovaza® and Microvascular Function in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00190970 -
The Effect of Ruboxistaurin on Small Fiber Function
|
Phase 2 | |
Completed |
NCT00101426 -
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
|
Phase 3 | |
Completed |
NCT00238550 -
Study of CBME in the Relief of Painful Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT05573685 -
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training
|
N/A | |
Recruiting |
NCT02341261 -
Activity for Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01822925 -
Study of DA-9801 to Treat Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT01690962 -
A Nutritional Intervention for Diabetic Neuropathy
|
N/A | |
Terminated |
NCT00993018 -
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
|
Phase 2 | |
Withdrawn |
NCT02315235 -
The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy
|
N/A | |
Completed |
NCT00496457 -
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT02606747 -
The Balance Control Mechanism of DPN Patients
|
N/A | |
Completed |
NCT02068027 -
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
|
Phase 2 |